Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

TORONTO, June 03, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Defining The Next Generation Of Coronavirus Stocks: This Company Comes into Focus

Revive Therapeutics Ltd. (OTC: RVVTF) (CSE: RVV): Management Believes That The Company…